<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: 667, L.P. -->
          <cik>0001551139</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001359931</issuerCik>
      <issuerName>Protara Therapeutics, Inc.</issuerName>
      <secFileNumber>001-36694</secFileNumber>
      <issuerAddress>
        <com:street1>345 Park Avenue South</com:street1>
        <com:street2>Third Floor</com:street2>
        <com:city>New York</com:city>
        <com:stateOrCountry>NY</com:stateOrCountry>
        <com:zipCode>10010</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>646-844-0337</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>667, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Former Affiliate</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Canaccord Genuity LLC</name>
        <address>
          <com:street1>99 High Street, Suite 1200</com:street1>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02110</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>26755</noOfUnitsSold>
      <aggregateMarketValue>161584.00</aggregateMarketValue>
      <noOfUnitsOutstanding>53587260</noOfUnitsOutstanding>
      <approxSaleDate>02/24/2026</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/08/2025</acquiredDate>
      <natureOfAcquisitionTransaction>See Remark 2</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>26755</amountOfSecuritiesAcquired>
      <paymentDate>12/08/2025</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>(1) 667, L.P. is affiliated with Baker Brothers Life Sciences, L.P. Baker Bros. Advisors LP serves as the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. Baker Brothers Life Sciences, L.P. is filing separately for the sale of 322,039 shares of common stock ("Common Stock") of Protara Therapeutics, Inc. (the "Issuer"), which along with the reported sales in this form by 667, L.P. totals 348,794 shares of Common Stock. (2) Common Stock acquired in underwritten public offering.</remarks>
    <noticeSignature>
      <noticeDate>02/24/2026</noticeDate>
      <signature>By: BAKER BROS. ADVISORS LP, mgmt company and IA to 667, L.P., /s/ Scott L. Lessing, President</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
